Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes for the Prophylaxis and Treatment of EBV, CMV, and Adenovirus Infection Post Allogeneic Stem Cell Transplant (VIRAGE)

NCT01070797 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT01070797
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01070797 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes for the Prophylaxis and Treatment of EBV, CMV, and Adenovirus Infection Post Allogeneic Stem Cell Transplant (VIRAGE)
Lead sponsor
Baylor College of Medicine
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2011
Completion date
April 30, 2014
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adenovirus infection, cytomegalovirus infections, epstein-barr virus infections, stem cell transplant